Gout Treat-to-Target Moves Into Primary Care: A Practical Guideline Update
The gout treat-to-target approach asks primary care clinicians to lower serum urate to a measured goal, not just to chase flares. Here is what to start, when, and for how long.
The Story at a Glance:
- The gout treat-to-target strategy is strongly recommended: titrate urate-lowering therapy to a serum urate target below 6 mg/dL.
- Start urate-lowering therapy in patients with two or more flares per year, tophi, or radiographic joint damage.
- Allopurinol is the preferred first-line agent for everyone, including those with stage 3 or worse chronic kidney disease.
- Run anti-inflammatory flare prophylaxis for at least three to six months when starting therapy.
What Happened
The gout treat-to-target approach is the central recommendation of the American College of Rheumatology (ACR) gout guideline, which prioritizes lowering serum urate to a defined goal over treating symptoms alone. It frames gout as a chronic crystal-deposition disease rather than a series of isolated attacks.
The guideline issued 42 recommendations, 16 of them strong. It names allopurinol as the preferred first-line urate-lowering therapy (ULT) and sets a serum urate (SU) target below 6 mg/dL, reached by gradual dose titration guided by repeat blood tests.
Why Gout Treat-to-Target Matters in Primary Care
Most gout is diagnosed and managed by primary care clinicians, yet urate is often left unmonitored and ULT under-titrated. Adopting a measured serum urate goal converts gout from reactive flare management into a controllable chronic condition.
Sustained urate below the solubility threshold dissolves existing crystal deposits over time, shrinking tophi and reducing recurrent flares. The lower the urate is driven and held, the faster those deposits clear.
Key Numbers
The practical thresholds a primary care clinician needs are concrete and easy to apply at the point of care.
- Serum urate target: below 6 mg/dL, maintained long term; below 5 mg/dL is favored for severe tophaceous disease.
- When to start ULT: two or more flares per year, tophi, or radiographic damage (strong); after a first flare with chronic kidney disease, urate above 9 mg/dL, or urolithiasis (conditional).
- Starting doses: allopurinol 100 mg/day or less (lower in chronic kidney disease); febuxostat under 40 mg/day.
- Prophylaxis duration: at least three to six months, extended while flares continue.
- Number needed to treat: in patients with no prior flare, about 24 treated for three years to prevent one flare — the basis for not treating asymptomatic hyperuricemia.
What Experts Are Saying
“Targeting hyperuricemia to prevent flares is key.” — Primary care continuing education summary of the ACR gout guideline
Not everyone agrees on scope. The American College of Physicians has favored a treat-to-symptoms approach for patients with infrequent flares, declining to endorse routine urate targets — a contrast that explains much of the variation primary care clinicians encounter between guidelines, according to recent reviews of urate-lowering therapy.
What’s Next
Expect continued debate over whether to treat after a first flare and over the role of imaging-detected crystal deposits in asymptomatic patients. Ongoing comparative-effectiveness trials are testing treat-to-target against usual care in real-world primary care settings, and head-to-head data continue to inform allopurinol-versus-febuxostat choices. HLA-B*5801 testing before allopurinol remains advised for higher-risk ancestries.
Bottom Line
- Adopt gout treat-to-target: titrate ULT to a serum urate below 6 mg/dL and recheck the level, do not dose by symptoms.
- Identify candidates early — two or more flares a year, tophi, or radiographic damage warrant starting therapy.
- Start allopurinol low, even in chronic kidney disease, and escalate; co-prescribe flare prophylaxis for three to six months.
- Counsel patients that ULT is long-term and that flares may rise briefly before crystal burden falls.
Sources
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 2020. ACR 2020 Gout Guideline (Arthritis Care & Research)
- American College of Rheumatology. ACR Releases Gout Management Guideline With Emphasis on Treat-to-Target. ACR Press Release, 2020. ACR Press Release on the Gout Guideline
- The Rheumatologist. Gout Management Recommendations from the ACR’s 2020 Guideline. 2020. The Rheumatologist — ACR Guideline Summary
- Schurenberg E, Huddleston EM, Saag KG. Urate Lowering Therapy in Primary Care: Rheum for Improvement. Exploration of Musculoskeletal Diseases, 2025. Urate-Lowering Therapy in Primary Care (DOI)